SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer

被引：0
|
作者：
Montal, R. [1 ]
Merche, M. -V. [1 ]
Anta, B. [2 ]
Martinez, N. [2 ]
Santos, C. [1 ,3 ]
Sanjuan, X. [4 ]
Paules, M. J. [5 ]
Perez Martin, F. J. [6 ]
Azuara, D. [3 ]
Salazar, R. [1 ,3 ]
Rojas, J. M. [2 ]
机构：
[1] Inst Catala Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[2] Inst Salud Carlos III UFIEC, Majadahonda, Spain
[3] Inst Catala Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Spain
[5] HUB, IDIBELL, Interdisciplinary Comm Esophagogastr Tumours, Lhospitalet De Llobregat, Spain
[6] Inst Catala Oncol ICO LHospitalet, IDIBELL, Clin Res Unit, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-195
引用
收藏
页数：1
相关论文
共 50 条
  • [41] KRAS mutation testing in metastatic colorectal cancer
    Cong Tan
    World Journal of Gastroenterology, 2012, (37) : 5171 - 5180
  • [42] KRAS mutation testing in metastatic colorectal cancer
    Tan, Cong
    Du, Xiang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (37) : 5171 - 5180
  • [43] KRAS mutations in primary and metastatic colorectal cancer
    Han, Cheng-Bo
    Li, Fan
    Ma, Jie-Tao
    Zou, Hua-Wei
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (05) : 731 - 732
  • [44] KRAS MUTATIONAL STATUS AS PREDICTIVE BIOMARKER OF RESPONSE TO OXALIPLATIN IN METASTATIC COLORECTAL CANCER
    Basso, M.
    Strippoli, A.
    Orlandi, A.
    Schinzari, G.
    Quirino, M.
    Trigila, N.
    D'Argento, E.
    Quaranta, A.
    Di Lascio, S.
    Amoruso, A.
    Cursio, E.
    Cassano, A.
    Barone, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 78 - 78
  • [45] KRAS mutations in primary and metastatic colorectal cancer
    Cheng-Bo Han
    Fan Li
    Jie-Tao Ma
    Hua-Wei Zou
    International Journal of Colorectal Disease, 2013, 28 : 731 - 732
  • [46] KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
    J-N Vauthey
    S Kopetz
    T A Aloia
    A Andreou
    British Journal of Cancer, 2012, 107 : 1442 - 1443
  • [47] Development of a mouse model of KRAS mutated colorectal cancer tumorigenesis
    Maitra, Radhashree
    Venkatesh, Madhu Kumar
    Augustine, Titto Alby
    Chandy, Carol
    Liu, Qiang
    Goel, Sanjay
    CANCER RESEARCH, 2017, 77
  • [48] Novel therapeutic strategy for Kras mutated colorectal cancer and PDAC
    Obi, Natsuno
    Takeda, Mizuho
    Masuda, Tatsuya
    Yanagida, Yohei
    Kobayakawa, Atsushi
    Sakuramoto, Naoya
    Hada, Asuka
    Horiuchi, Ayaka
    Sasaki, Asami
    Takeda, Kanako
    Matsuo, Hidemasa
    Adachi, Souichi
    Kamikubo, Yasuhiko
    CANCER SCIENCE, 2021, 112 : 434 - 434
  • [49] MicroRNA signature associated with KRAS-mutated colorectal cancer
    Andreoiu, O-M
    Dobre, M.
    Pirvu, I-R
    Vasilescu, F.
    Herlea, V.
    Becheanu, G.
    VIRCHOWS ARCHIV, 2017, 471 : S161 - S162
  • [50] THE ROLE OF ASPARAGINE SYNTHETASE IN COLORECTAL CANCER WITH MUTATED KRAS.
    Toda, K.
    Kawada, K.
    Iwamoto, M.
    Inamoto, S.
    Hasegawa, S.
    Sakai, Y.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E117 - E118
12345